Amended Statement of Ownership (sc 13g/a)
July 15 2019 - 04:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
Sunesis
Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
867328502
(CUSIP Number)
July 15, 2019
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to
designate the rule pursuant to which this Schedule is filed.
☐ Rule
13d-1(b)
☒ Rule
13d-1(c)
☐ Rule
13d-1(d)
*
|
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
CUSIP No. 867328502
|
|
SCHEDULE 13G
|
|
Page
2
of 11
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON OR
I.R.S.
IDENTIFICATION NO. OF ABOVE PERSON
Aisling Capital IV, LP
|
2
|
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP
(a) ☐ (b) ☒
|
3
|
|
SEC USE ONLY
|
4
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Delaware
|
|
|
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
5
|
|
SOLE VOTING POWER
10,100,000
|
|
6
|
|
SHARED VOTING POWER
0
|
|
7
|
|
SOLE DISPOSITIVE POWER
10,100,000
|
|
8
|
|
SHARED DISPOSITIVE POWER
0
|
|
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10,100,000 (See Item 4)
|
10
|
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
☐
|
11
|
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (9)
10.0%
|
12
|
|
TYPE OF REPORTING
PERSON
PN
|
|
|
|
|
|
CUSIP No. 867328502
|
|
SCHEDULE 13G
|
|
Page
3
of 11
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON OR
I.R.S.
IDENTIFICATION NO. OF ABOVE PERSON
Aisling Capital Partners IV,
LP
|
2
|
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP
(a) ☐ (b) ☒
|
3
|
|
SEC USE ONLY
|
4
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Delaware
|
|
|
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
5
|
|
SOLE VOTING POWER
10,100,000
|
|
6
|
|
SHARED VOTING POWER
0
|
|
7
|
|
SOLE DISPOSITIVE POWER
10,100,000
|
|
8
|
|
SHARED DISPOSITIVE POWER
0
|
|
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10,100,000 (See Item 4)
|
10
|
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
☐
|
11
|
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (9)
10.0%
|
12
|
|
TYPE OF REPORTING
PERSON
PN
|
|
|
|
|
|
CUSIP No. 867328502
|
|
SCHEDULE 13G
|
|
Page
4
of 11
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON OR
I.R.S.
IDENTIFICATION NO. OF ABOVE PERSON
Aisling Capital Partners IV
LLC
|
2
|
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP
(a) ☐ (b) ☒
|
3
|
|
SEC USE ONLY
|
4
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Delaware
|
|
|
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
5
|
|
SOLE VOTING POWER
10,100,000
|
|
6
|
|
SHARED VOTING POWER
0
|
|
7
|
|
SOLE DISPOSITIVE POWER
10,100,000
|
|
8
|
|
SHARED DISPOSITIVE POWER
0
|
|
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10,100,000 (See Item 4)
|
10
|
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
☐
|
11
|
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (9)
10.0%
|
12
|
|
TYPE OF REPORTING
PERSON
OO
|
|
|
|
|
|
CUSIP No. 867328502
|
|
SCHEDULE 13G
|
|
Page
5
of 11
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON OR
I.R.S.
IDENTIFICATION NO. OF ABOVE PERSON
Steve Elms
|
2
|
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP
(a) ☐ (b) ☒
|
3
|
|
SEC USE ONLY
|
4
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
United
States
|
|
|
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
5
|
|
SOLE VOTING POWER
0
|
|
6
|
|
SHARED VOTING POWER
10,100,000
|
|
7
|
|
SOLE DISPOSITIVE POWER
0
|
|
8
|
|
SHARED DISPOSITIVE POWER
10,100,000
|
|
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10,100,000 (See Item 4)
|
10
|
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
☐
|
11
|
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (9)
10.0%
|
12
|
|
TYPE OF REPORTING
PERSON
IN
|
|
|
|
|
|
CUSIP No. 867328502
|
|
SCHEDULE 13G
|
|
Page
6
of 11
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON OR
I.R.S.
IDENTIFICATION NO. OF ABOVE PERSON
Andrew Schiff
|
2
|
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP
(a) ☐ (b) ☒
|
3
|
|
SEC USE ONLY
|
4
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
United
States
|
|
|
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
5
|
|
SOLE VOTING POWER
0
|
|
6
|
|
SHARED VOTING POWER
10,100,000
|
|
7
|
|
SOLE DISPOSITIVE POWER
0
|
|
8
|
|
SHARED DISPOSITIVE POWER
10,100,000
|
|
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10,100,000 (See Item 4)
|
10
|
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
☐
|
11
|
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (9)
10.0%
|
12
|
|
TYPE OF REPORTING
PERSON
IN
|
|
|
|
|
|
CUSIP No. 867328502
|
|
SCHEDULE 13G
|
|
Page
7
of 11
|
ITEM 1.
|
|
(a)
|
Name of Issuer:
|
Sunesis Pharmaceuticals, Inc. (the Issuer)
|
(b)
|
Address of Issuers Principal Executive Offices:
|
395 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080
ITEM 2.
|
|
(a)
|
Name of Person Filing:
|
This Schedule 13G (this Statement) is being filed by the following persons (collectively, the Reporting Persons):
|
(i)
|
Aisling Capital IV, LP, a Delaware limited partnership (Aisling);
|
|
(ii)
|
Aisling Capital Partners IV, LP, a Delaware limited partnership (Aisling Partners), a general
partner of Aisling;
|
|
(iii)
|
Aisling Capital Partners IV LLC, a Delaware limited liability company (Aisling Partners GP), a
general partner of Aisling Partners;
|
|
(iv)
|
Mr. Steve Elms, a managing member of Aisling Partners GP;
|
|
(v)
|
Mr. Andrew Schiff, a managing member of Aisling Partners GP.
|
|
(b)
|
Address of Principal Business Office, or if None, Residence:
|
The address of the principal business offices of each of the Reporting Persons is 888 Seventh Avenue, 12th Floor, New York, New York 10106.
|
(i)
|
Aisling - a Delaware limited partnership
|
|
(ii)
|
Aisling Partners - a Delaware limited partnership
|
|
(iii)
|
Aisling Partners GP - a Delaware limited liability company
|
|
(iv)
|
Mr. Elms - United States
|
|
(v)
|
Mr. Schiff - United States
|
|
(d)
|
Title of Class of Securities:
|
Common Stock, par value $0.0001 per share (the Common Stock).
867328502
ITEM 3.
|
IF THIS STATEMENT IS FILED PURSUANT TO
§240.13D-1(B)
OR
240.13D-2(B)
OR (C), CHECK WHETHER THE PERSON FILING IS A:
|
|
(a)
|
☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)
|
|
(b)
|
☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c)
|
|
(c)
|
☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c)
|
|
(d)
|
☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C.
80a-8)
|
|
(e)
|
☐ An investment adviser in accordance with
§240.13d-1(b)(1)(ii)(E)
|
|
(f)
|
☐ An employee benefit plan or endowment fund in accordance with
§240.13d-1(b)(1)(ii)(F);
|
|
|
|
|
|
CUSIP No. 867328502
|
|
SCHEDULE 13G
|
|
Page
8
of 11
|
|
(g)
|
☐ A Parent holding company or control person in accordance with
§240.13d-1(b)(1)(ii)(G);
|
|
(h)
|
☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.
1813)
|
|
(i)
|
☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of
the Investment Company Act of 1940 (15 U.S.C.
80a-3)
|
|
(j)
|
☐ A
non-U.S.
institution in accordance with
§240.13d-1(b)(1)(ii)(J);
|
|
(k)
|
☐ Group, in accordance with
§240.13d-1(b)(1)(ii)(J).
|
|
(a)
|
Amount beneficially owned:
|
Each of the Reporting Persons may be deemed to beneficially own an aggregate of 10,100,000 shares of Common Stock.
Based on the calculations made in accordance with Rule
13d-3(d),
each of the Reporting Persons may be
deemed to beneficially own approximately 10.0% of the outstanding Common Stock as of the date hereof.
All percentages of ownership of the
Common Stock by Reporting Persons presented in this Statement assume an aggregate of 100,911,754 shares of Common Stock issued and outstanding, as reported in the Issuers Prospectus Supplement dated July 10, 2019, filed with the Securities and
Exchange Commission on July 12, 2019.
|
(c)
|
Number of shares as to which such person has:
|
|
(i), (iii)
|
Sole power to vote or to direct the vote/Sole power to dispose of or to direct the disposition of:
|
As of the date hereof, each of Aisling, Aisling Partners and Aisling Partners GP may be deemed to have sole power to
direct the voting and disposition of the 10,100,000 shares of Common Stock beneficially owned by Aisling.
|
(ii), (iv)
|
Shared power to vote or to direct the vote/Shared power to dispose of or to direct the disposition of:
|
By virtue of the relationships between and among the Reporting Persons as described in Item 2, each of Messrs. Elms and
Schiff may be deemed to share the power to direct the voting and the disposition of the 10,100,000 shares of Common Stock beneficially owned by Aisling as of the date hereof.
ITEM 5.
|
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
|
Not Applicable.
If this
statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
|
|
|
|
|
CUSIP No. 867328502
|
|
SCHEDULE 13G
|
|
Page
9
of 11
|
ITEM 6.
|
OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
|
The partners of Aisling have the right to participate in the receipt of dividends from, or proceeds from the sale of, the Common Stock held for
the account of Aisling in accordance with their ownership interests in Aisling.
ITEM 7.
|
IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE
PARENT HOLDING COMPANY.
|
Not Applicable.
ITEM 8.
|
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
|
Not Applicable.
ITEM 9.
|
NOTICE OF DISSOLUTION OF GROUP
|
Not Applicable.
By signing below I hereby certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
|
|
|
|
|
CUSIP No. 867328502
|
|
SCHEDULE 13G
|
|
Page
10
of 11
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: July 15, 2019
|
|
|
AISLING CAPITAL IV, LP
|
|
By: Aisling Capital Partners IV, LP,
As its General Partner
|
|
By: Aisling Capital Partners IV LLC,
As its General Partner
|
|
|
By:
|
|
/s/ Andrew Schiff
|
|
|
Name: Andrew Schiff
Title: Managing
Member
|
|
AISLING CAPITAL PARTNERS IV, LP
|
|
By: Aisling Capital Partners IV LLC,
As its General Partner
|
|
|
By:
|
|
/s/ Andrew Schiff
|
|
|
Name: Andrew Schiff
Title: Managing
Member
|
|
AISLING CAPITAL PARTNERS IV LLC
|
|
|
By:
|
|
/s/ Andrew Schiff
|
|
|
Name: Andrew Schiff
Title: Managing
Member
|
|
STEVE ELMS
|
|
|
By:
|
|
/s/ Steve Elms
|
|
ANDREW SCHIFF
|
|
|
By:
|
|
/s/ Andrew Schiff
|
|
|
|
|
|
CUSIP No. 867328502
|
|
SCHEDULE 13G
|
|
Page
11
of 11
|
EXHIBIT INDEX
|
|
|
Exhibit 1.
|
|
Joint Filing Agreement as required by Rule
13d-1(k)(1)
under the Securities Exchange Act of 1934, as amended (previously filed).
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Mar 2023 to Mar 2024